1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  05/26 11:35:10 am EDT
10546.00 GBX   -0.51%
01:07pCancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
RE
05/25ASTRAZENECA : JP Morgan keeps its Buy rating
MD
05/25French health body backs new COVID vaccine booster campaign for this autumn
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Says Liver Cancer Combination Therapy Improved Overall Survival in Late-Stage Trial

01/19/2022 | 03:49am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.51% 10546 Delayed Quote.22.15%
ON SEMICONDUCTOR CORPORATION 5.49% 59.33 Delayed Quote.-17.20%
All news about ASTRAZENECA PLC
01:07pCancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
RE
05/25ASTRAZENECA : JP Morgan keeps its Buy rating
MD
05/25French health body backs new COVID vaccine booster campaign for this autumn
RE
05/24Indian vaccine giant Serum plans African plant in global expansion
RE
05/24Danske Bank Initiates Coverage on AstraZeneca With Buy Rating
MT
05/24Vaxzevria approved in the EU as third dose booster against COVID-19
AQ
05/24AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
AQ
05/24AstraZeneca COVID-19 vaccine approved in the EU as third dose booster against COVID-19
AQ
05/24Trial Scheduled For April 2024 In BMS Patent Case Against AstraZeneca Regarding Anti-PD..
AQ
05/23EU Drug Regulator Approves AstraZeneca's COVID-19 Vaccine as Third-Dose Booster
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 665 M - -
Net income 2022 5 151 M - -
Net Debt 2022 23 311 M - -
P/E ratio 2022 40,2x
Yield 2022 2,22%
Capitalization 206 B 206 B -
EV / Sales 2022 5,24x
EV / Sales 2023 4,81x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 132,74 $
Average target price 143,66 $
Spread / Average Target 8,22%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC22.15%206 235
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530